Last gasp for Auriculin

After giving its Auriculin atrial natriuretic peptide another college try - this time in a trial for oliguric acute renal failure - Scios Inc. (SCIO, Mountain View, Calif.) and partner Genentech Inc. (GNE, South San Francisco, Calif.) have suspended development of the compound indefinitely and SCIO will shift its focus to other candidates in clinical trials.

SCIO halted its 250-patient Phase III trial

Read the full 622 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE